JPMorgan analyst Anupam Rama sees a favorable setup for shares of Sarepta Therapeutics(SRPT) into the company's R&D day on Tuesday, June 19. His scenario analysis points to a "very favorable" reward/risk profile of 20%-50% upside versus 10%-25% downside. If the gene therapy data meets or beats expectations, Sarepta will clearly be in the pole position in the micro-dystrophin space, Rama tells investors in a research note. The analyst adds that if the Sarepta micro-dystrophin data are viewed positively next week, a clear bar will have been set that Solid Biosciences (SLDB) will need to meet or beat. Rama continues to see risk to Solid shares ahead of next week's readout from Sarepta. He has an Overweight rating on Sarepta with an $87 price target and Underweight rating on Solid Biosciences with a $10 price target.